Immix Biopharma (IMMX) EBITDA (2021 - 2026)

Immix Biopharma has disclosed EBITDA across 6 years of filings, most recently posting -$10.0 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$10.0 million, down 121.86% year-over-year; the trailing twelve-month figure through Mar 2026 was -$34.9 million (down 66.38% YoY), and the FY2025 annual result was -$29.4 million, down 35.07% from the prior year.
• EBITDA came in at -$10.0 million for Q1 2026 at Immix Biopharma, up from -$10.7 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$1.3 million in Q1 2022 to a low of -$10.7 million in Q4 2025.
• The 5-year median for EBITDA is -$4.5 million (2025), against an average of -$5.0 million.
• Peak annual rise in EBITDA reached 83.41% in 2022, while the deepest fall reached 685.2% in 2022.
• Immix Biopharma's EBITDA stood at -$3.8 million in 2022, then sank by 32.5% to -$5.0 million in 2023, then dropped by 0.07% to -$5.0 million in 2024, then tumbled by 113.58% to -$10.7 million in 2025, then gained by 6.07% to -$10.0 million in 2026.
• The last three EBITDA figures came in at -$10.0 million (Q1 2026), -$10.7 million (Q4 2025), and -$7.6 million (Q3 2025), per Business Quant data.